The Overall Survival Data Of Future-C-Plus: Combination Of Famitinib With Camrelizumab Plus Nab-Paclitaxel As First-Line Treatment For Advanced, Immunomodulatory Triple-Negative Breast Cancer, An Open-Label, Single-Arm, Phase II Trial
Camrelizumab;Famitinib;Nab-Paclitaxel
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: The Overall Survival Data Of Future-C-Plus: Combination Of Famitinib With Camrelizumab Plus Nab-Paclitaxel As First-Line Treatment For Advanced, Immunomodulatory Triple-Negative Breast Cancer, An Open-Label, Single-Arm, Phase II Trial ### Output: Camrelizumab;Famitinib;Nab-Paclitaxel